Central autonomic network dysfunction and plasma Alzheimer's disease biomarkers in older adults.
Humans
Female
Alzheimer Disease
/ blood
Aged
Male
Biomarkers
/ blood
Amyloid beta-Peptides
/ blood
Magnetic Resonance Imaging
Brain
/ diagnostic imaging
Peptide Fragments
/ blood
Autonomic Nervous System
/ physiopathology
Glial Fibrillary Acidic Protein
/ blood
Aged, 80 and over
Neurofilament Proteins
/ blood
Autonomic Nervous System Diseases
/ blood
Alzheimer’s Disease
Aβ42/40
Central autonomic network
Glial fibrillary acidic protein
Neurofilament light chain
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
08 Jun 2024
08 Jun 2024
Historique:
received:
22
03
2024
accepted:
24
05
2024
medline:
9
6
2024
pubmed:
9
6
2024
entrez:
8
6
2024
Statut:
epublish
Résumé
Higher order regulation of autonomic function is maintained by the coordinated activity of specific cortical and subcortical brain regions, collectively referred to as the central autonomic network (CAN). Autonomic changes are frequently observed in Alzheimer's disease (AD) and dementia, but no studies to date have investigated whether plasma AD biomarkers are associated with CAN functional connectivity changes in at risk older adults. Independently living older adults (N = 122) without major neurological or psychiatric disorder were recruited from the community. Participants underwent resting-state brain fMRI and a CAN network derived from a voxel-based meta-analysis was applied for overall, sympathetic, and parasympathetic CAN connectivity using the CONN Functional Toolbox. Sensorimotor network connectivity was studied as a negative control. Plasma levels of amyloid (Aβ All autonomic networks were positively associated with Aβ The present study findings suggest that CAN function is associated with plasma AD biomarker levels. Specifically, lower CAN functional connectivity is associated with decreased plasma Aβ
Sections du résumé
BACKGROUND
BACKGROUND
Higher order regulation of autonomic function is maintained by the coordinated activity of specific cortical and subcortical brain regions, collectively referred to as the central autonomic network (CAN). Autonomic changes are frequently observed in Alzheimer's disease (AD) and dementia, but no studies to date have investigated whether plasma AD biomarkers are associated with CAN functional connectivity changes in at risk older adults.
METHODS
METHODS
Independently living older adults (N = 122) without major neurological or psychiatric disorder were recruited from the community. Participants underwent resting-state brain fMRI and a CAN network derived from a voxel-based meta-analysis was applied for overall, sympathetic, and parasympathetic CAN connectivity using the CONN Functional Toolbox. Sensorimotor network connectivity was studied as a negative control. Plasma levels of amyloid (Aβ
RESULTS
RESULTS
All autonomic networks were positively associated with Aβ
CONCLUSION
CONCLUSIONS
The present study findings suggest that CAN function is associated with plasma AD biomarker levels. Specifically, lower CAN functional connectivity is associated with decreased plasma Aβ
Identifiants
pubmed: 38851772
doi: 10.1186/s13195-024-01486-9
pii: 10.1186/s13195-024-01486-9
doi:
Substances chimiques
Biomarkers
0
Amyloid beta-Peptides
0
Peptide Fragments
0
amyloid beta-protein (1-42)
0
Glial Fibrillary Acidic Protein
0
Neurofilament Proteins
0
amyloid beta-protein (1-40)
0
neurofilament protein L
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
124Subventions
Organisme : CIHR
ID : DFD-170763
Pays : Canada
Organisme : NIH HHS
ID : K24AG081325
Pays : United States
Organisme : NIH HHS
ID : P30AG066519
Pays : United States
Organisme : NIH HHS
ID : R01AG064228
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Benarroch EE. The central autonomic network: functional organization, dysfunction, and perspective. Mayo Clin Proc. 1993;68:988–1001.
doi: 10.1016/S0025-6196(12)62272-1
pubmed: 8412366
Jänig W. Integrative action of the autonomic nervous system: neurobiology of homeostasis. Cambridge: Cambridge University Press; 2006.
doi: 10.1017/CBO9780511541667
Beissner F, Meissner K, Bär KJ, Napadow V. The autonomic brain: an activation likelihood estimation meta-analysis for central processing of autonomic function. J Neurosci. 2013;33:10503–11.
doi: 10.1523/JNEUROSCI.1103-13.2013
pubmed: 23785162
pmcid: 3685840
Engelhardt E, Laks J. Alzheimer disease neuropathology: understanding autonomic dysfunction. Dement Neuropsychol. 2008;2:183–91.
doi: 10.1590/S1980-57642009DN20300004
pubmed: 29213568
pmcid: 5619463
Collins O, Dillon S, Finucane C, Lawlor B, Kenny RA. Parasympathetic autonomic dysfunction is common in mild cognitive impairment. Neurobiol Aging. 2012;33:2324–33.
doi: 10.1016/j.neurobiolaging.2011.11.017
pubmed: 22188719
Tulbă D, Cozma L, Popescu BO, Davidescu EI. Dysautonomia in Alzheimer’s disease. Med (Kaunas). 2020;56.
Jensen-Dahm C, et al. Autonomic dysfunction in patients with mild to moderate Alzheimer’s disease. J Alzheimers Dis. 2015;47:681–9.
doi: 10.3233/JAD-150169
pubmed: 26401703
Royall DR, Gao JH, Kellogg DL Jr. Insular Alzheimer’s disease pathology as a cause of age-related autonomic dysfunction and mortality in the non-demented elderly. Med Hypotheses. 2006;67:747–58.
doi: 10.1016/j.mehy.2005.10.036
pubmed: 16806725
Valenza G, et al. The central autonomic network at rest: uncovering functional MRI correlates of time-varying autonomic outflow. NeuroImage. 2019;197:383–90.
doi: 10.1016/j.neuroimage.2019.04.075
pubmed: 31055043
Ding K, et al. Central autonomic network functional connectivity: correlation with baroreflex function and cardiovascular variability in older adults. Brain Struct Funct. 2020;225:1575–85.
doi: 10.1007/s00429-020-02075-w
pubmed: 32350644
pmcid: 7292781
Nair SS et al. Investigation of autonomic dysfunction in Alzheimer’s disease-a computational model-based approach. Brain Sci. 2023;13.
Nonogaki Z, Umegaki H, Makino T, Suzuki Y, Kuzuya M. Relationship between cardiac autonomic function and cognitive function in Alzheimer’s disease. Geriatr Gerontol Int. 2017;17:92–8.
doi: 10.1111/ggi.12679
pubmed: 26643357
Brier MR, Thomas JB, Ances BM. Network dysfunction in Alzheimer’s disease: refining the disconnection hypothesis. Brain Connect. 2014;4:299–311.
doi: 10.1089/brain.2014.0236
pubmed: 24796856
pmcid: 4064730
Sheline YI, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry. 2010;67:584–7.
doi: 10.1016/j.biopsych.2009.08.024
pubmed: 19833321
Neufang S, et al. Disconnection of frontal and parietal areas contributes to impaired attention in very early Alzheimer’s disease. J Alzheimers Dis. 2011;25:309–21.
doi: 10.3233/JAD-2011-102154
pubmed: 21422523
Allen G, et al. Reduced hippocampal functional connectivity in Alzheimer disease. Arch Neurol. 2007;64:1482–7.
doi: 10.1001/archneur.64.10.1482
pubmed: 17923631
Wang L, et al. Changes in hippocampal connectivity in the early stages of Alzheimer’s disease: evidence from resting state fMRI. NeuroImage. 2006;31:496–504.
doi: 10.1016/j.neuroimage.2005.12.033
pubmed: 16473024
Dautricourt S, et al. Longitudinal changes in hippocampal network connectivity in Alzheimer’s disease. Ann Neurol. 2021;90:391–406.
doi: 10.1002/ana.26168
pubmed: 34279043
pmcid: 9291910
Johnson-Greene D, Dementia Rating Scale-2 (DRS-2) By, Jurica PJ, Leitten CL. and S. Mattis: psychological assessment resources, 2001. Arch Clin Neuropsychol. 2004;19:145–147.
Kapoor A et al. Increased levels of circulating angiogenic cells and signaling proteins in older adults with cerebral small vessel disease. Front Aging Neurosci. 2021;13.
Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connect. 2012;2:125–41.
doi: 10.1089/brain.2012.0073
pubmed: 22642651
Nieto-Castanon A. Handbook of functional connectivity magnetic resonance imaging methods in CONN. 2020.
Grothe MJ, et al. Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy. Neurology. 2021;97:e1229–42.
doi: 10.1212/WNL.0000000000012513
pubmed: 34266917
pmcid: 8480485
Hayes AF. Introduction to mediation, moderation, and conditional process analysis: A regression-based approach. Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. Guilford Press, New York, NY, US. 2013, pp. xvii, 507-xvii, 507.
Korthauer K, et al. A practical guide to methods controlling false discoveries in computational biology. Genome Biol. 2019;20:118.
doi: 10.1186/s13059-019-1716-1
pubmed: 31164141
pmcid: 6547503
Mayer CA, et al. Blood levels of glial fibrillary acidic protein (GFAP) in patients with neurological diseases. PLoS ONE. 2013;8:e62101.
doi: 10.1371/journal.pone.0062101
pubmed: 23626774
pmcid: 3633915
Abdelhak A, et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat Reviews Neurol. 2022;18:158–72.
doi: 10.1038/s41582-021-00616-3
Amalia L. Glial fibrillary acidic protein (GFAP): Neuroinflammation Biomarker in Acute ischemic stroke. J Inflamm Res. 2021;14:7501–6.
doi: 10.2147/JIR.S342097
pubmed: 35002283
pmcid: 8722682
Benedet AL, et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 2021;78:1471–83.
doi: 10.1001/jamaneurol.2021.3671
pubmed: 34661615
Kim KY, Shin KY, Chang K-A. GFAP as a potential biomarker for Alzheimer’s disease: a systematic review and meta-analysis. Cells. 2023. https://doi.org/10.3390/cells12091309 .
doi: 10.3390/cells12091309
pubmed: 38201284
pmcid: 10778393
Chatterjee P, et al. Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer’s disease: associations with Aβ-PET, neurodegeneration, and cognition. Alzheimer’s Dement. 2023;19:2790–804.
doi: 10.1002/alz.12879
Pereira JB, et al. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease. Brain. 2021;144:3505–16.
doi: 10.1093/brain/awab223
pubmed: 34259835
pmcid: 8677538
Giacomucci G, et al. Plasma neurofilament light chain as a biomarker of Alzheimer’s disease in subjective cognitive decline and mild cognitive impairment. J Neurol. 2022;269:4270–80.
doi: 10.1007/s00415-022-11055-5
pubmed: 35288777
pmcid: 9293849
Lewczuk P, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Res Ther. 2018;10:71.
doi: 10.1186/s13195-018-0404-9
pubmed: 30055655
pmcid: 6064615
de Heus RAA, Olde Rikkert MGM, Tully PJ, Lawlor BA, Claassen J. Blood pressure variability and progression of clinical Alzheimer disease. Hypertension. 2019;74:1172–80.
doi: 10.1161/HYPERTENSIONAHA.119.13664
pubmed: 31542965
Jarczok MN, et al. Heart rate variability in the prediction of mortality: a systematic review and meta-analysis of healthy and patient populations. Neurosci Biobehav Rev. 2022;143:104907.
doi: 10.1016/j.neubiorev.2022.104907
Rovere MTL, Bigger JT, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet. 1998;351:478–84.
doi: 10.1016/S0140-6736(97)11144-8
pubmed: 9482439
deBoer RW, Karemaker JM, Strackee J. Hemodynamic fluctuations and baroreflex sensitivity in humans: a beat-to-beat model. Am J Physiol Heart Circ Physiol. 1987;253:H680–9.
doi: 10.1152/ajpheart.1987.253.3.H680
Lanfranchi PA, Somers VK. Arterial baroreflex function and cardiovascular variability: interactions and implications. Am J Physiol Regul Integr Comp Physiol. 2002;283:R815–826.
doi: 10.1152/ajpregu.00051.2002
pubmed: 12228049
Sible IJ, Bangen KJ, Blanken AE, Ho JK, Nation DA. Antemortem visit-to-visit blood pressure variability predicts cerebrovascular lesion burden in autopsy-confirmed Alzheimer’s disease. J Alzheimers Dis. 2021;83:65–75.
doi: 10.3233/JAD-210435
pubmed: 34250941
pmcid: 8820262
Sible IJ, Nation DA. I. on behalf of Alzheimer’s Disease Neuroimaging, visit-to-visit blood pressure variability and CSF Alzheimer disease biomarkers in cognitively unimpaired and mildly impaired older adults. Neurology. 2022;98:e2446–53.
doi: 10.1212/WNL.0000000000200302
pubmed: 35418462
pmcid: 9231834
Lohman T et al. Blood pressure variability, central autonomic network dysfunction and cerebral small vessel disease in APOE4 carriers. medRxiv. 2023.
Min J, et al. Modulating heart rate oscillation affects plasma amyloid beta and tau levels in younger and older adults. Sci Rep. 2023;13:3967.
doi: 10.1038/s41598-023-30167-0
pubmed: 36894565
pmcid: 9998394
Grajski KA, Bressler SL; Alzheimer’s Disease Neuroimaging Initiative. Differential medial temporal lobe and default-mode network functional connectivity and morphometric changes in Alzheimer’s disease. Neuroimage Clin. 2019;23:101860. https://doi.org/10.1016/j.nicl.2019.101860 . Epub 2019 May 18. PMID: 31158694; PMCID: PMC6545401.
Zhou Y, et al. Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer’s disease and mild cognitive impairment. Alzheimers Dement. 2008;4:265–70.
doi: 10.1016/j.jalz.2008.04.006
pubmed: 18631977
Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer’s disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA. 2004;101:4637–42.
doi: 10.1073/pnas.0308627101
pubmed: 15070770
pmcid: 384799
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239–59.
doi: 10.1007/BF00308809
pubmed: 1759558
Braak H, Thal DR, Ghebremedhin E, Del K, Tredici. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70:960–9.
doi: 10.1097/NEN.0b013e318232a379
pubmed: 22002422